Obesity management drugs are evolving from once-weekly GLP-1 receptor agonist injections to longer-acting candidates, ...
From once-weekly subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), longer-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback